Valeant Pharma (VRX) sued in New York Federal court over alleged overcharges - Reuters
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
(Updated - August 29, 2016 2:01 PM EDT)
Valeant Pharma (NYSE: VRX) was sued in New York Federal court over alleged overcharges, according to Reuters. The lawsuit was brought on behalf of so-called third party payors over alleged overcharges from January 2013 to October 2015.
Plaintiffs include New York hotel trade group's health benefits fund, and detectives endowment association of New York City, the report noted.
The lawsuit accuses Valeant of violating U.S. racketeer influenced and corrupt organizations act, or RICO, and seeks class action status, unspecified compensatory and triple damages.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Says SEC Requested Documents on Anti-Corruption Compliance in China; Reviewed with DoJ
- Volatility and Volume movement
- iPath S&P 500 VIX ST Futures ETN (NYSE: VXX) down 1.7%
Create E-mail Alert Related CategoriesLitigation, Short Sales, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!